LIPOCINE INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
LIPOCINE INC. (LPCN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $3.39 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-04
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $5.53, a 42.16% increase year-over-year.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $3.89.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2016-03-31 was $8.51.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-03-31 was $5.21.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $3.08, a 18.95% decline from fiscal 2024.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $3.80, a 38.61% decline from fiscal 2023.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $6.19, a 46.17% decline from fiscal 2022.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $11.50, a 1085.57% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $3.39 10-Q · filed 2026-08-04 | ||||
| 2026-03-31 | $5.53 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $3.08 10-K · filed 2026-03-10 | ||||
| 2025-06-30 | $3.32 10-Q · filed 2026-08-04 | ||||
| 2025-03-31 | $3.89 10-Q · filed 2026-05-07 | ||||
| 2024-12-31 | $3.80 10-K · filed 2026-03-10 | ||||
| 2023-12-31 | $6.19 10-K · filed 2025-03-13 | ||||
| 2022-12-31 | $11.50 10-K · filed 2024-03-07 | $0.53 10-K · filed 2023-03-10 | |||
| 2021-12-31 | $0.97 10-K · filed 2023-03-10 | ||||
| 2020-12-31 | $0.72 10-K · filed 2022-03-09 | ||||
| 2019-12-31 | $1.25 10-K · filed 2021-03-11 | ||||
| 2018-12-31 | $1.01 10-K · filed 2020-03-13 | ||||
| 2017-12-31 | $2.45 10-K · filed 2019-03-06 | ||||
| 2016-12-31 | $6.06 10-K · filed 2019-03-06 | ||||
| 2016-09-30 | $8.29 10-Q · filed 2016-11-08 | ||||
| 2016-06-30 | $8.29 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | $8.51 10-Q · filed 2016-05-09 | ||||
| 2015-12-31 | $6.60 10-K · filed 2018-03-12 | ||||
| 2015-09-30 | $6.32 10-Q · filed 2016-11-08 | ||||
| 2015-06-30 | $5.06 10-Q · filed 2016-08-09 | ||||
| 2014-12-31 | $5.45 10-K · filed 2017-03-06 | ||||
| 2014-09-30 | $5.48 10-Q · filed 2015-11-12 | ||||
| 2014-06-30 | $5.20 10-Q · filed 2015-08-11 | ||||
| 2014-03-31 | $5.21 10-Q · filed 2015-05-07 | ||||
| 2013-12-31 | $2.92 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |